Answers are grounded in this paper and cite their sources.
Novel palladium complexes show anti-ovarian cancer effects and antibacterial activity in different strains, suggesting potential therapeutic uses.
In this study, three new palladium (II) complexes with isatin-3-thiosemicarbazone (ITC) were prepared by reacting Pd(II) with ITC and phosphine or diamine ligands. Characterisation was done using CHN analysis, molar conductivity, FTIR spectroscopy, and ¹H, ¹³C, and ³¹P NMR spectroscopy. All analyses confirmed that the complexes exhibit a square planar structure around the Pd²⁺ ion. The ITC ligand displayed a bidentate coordination mode, binding through nitrogen and sulphur atoms. In vitro biological activity studies revealed excellent anti-ovarian cancer potential. Notably, the complex (Pd(ITC)(Phen))Cl₂ demonstrated only 5% cell survival at a 400 µM concentration, while the other two complexes, (Pd(ITC)₂)Cl₂ and (Pd(ITC)(PPh₃)Cl)Cl, did not exceed 10%. These results illustrate the strong ability of these complexes to inhibit cancer cell growth in vitro. Additionally, the three synthesised complexes demonstrated clear antibacterial activity against four bacterial strains: two Gram-positive (Streptococcus faecalis and Staphylococcus aureus) and two Gram-negative (E. coli and Pseudomonas aeruginosa). The activity was concentration-dependent, decreasing as the concentration lowered. The complex (Pd(ITC)(Phen))Cl₂ exhibited the highest antibacterial activity, particularly against Gram-positive bacteria, followed by (Pd(ITC)(PPh₃)Cl)Cl and (Pd(ITC)₂)Cl₂. These findings indicate the possible development of these complexes as therapeutic agents with anticancer and antibacterial properties, particularly in addressing bacterial resistance to conventional antibiotics.
No takes yet. Share an insight, caveat, or question.
Al-obaidi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: